Afatinib 40mg/day
Sponsors
Gunma University Graduate School of Medicine, Dokkyo Medical University, Okayama University Hospital, West Japan Oncology Group, Kagoshima University Hospital
Conditions
EGFR mutated, advanced lung adenocarcinomaLung CancerNon-small cell lung cancer
Phase 2
The feasibility study and biomarker research of afatinib in patients with previously treated advanced NSCLC harboring EGFR mutation
RecruitingJPRN-UMIN000015552
Start: 2014-10-28Target: 45Updated: 2026-06-29
A phase II, biomarker study using digital PCR method in EGFR mutated, advanced lung adenocarcinoma patients treated with afatinib. WJOG8114LTR
Active, not recruitingJPRN-UMIN000015847
Start: 2015-02-20Target: 55Updated: 2026-06-29
Unknown Phase
Phase 2 study of afatinib in patients with previously treated advanced non-sq NSCLC haboring EGFR mutation
Active, not recruitingJPRN-UMIN000014981
Start: 2014-08-01Target: 55Updated: 2026-06-29
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790M
Active, not recruitingJPRN-UMIN000015568
Start: 2014-12-01Target: 12Updated: 2026-06-29
Prospective study to investigate the resistant mechanism to afatinib treatment in EGFR mutation-positive non-small cell lung cancer
Active, not recruitingJPRN-UMIN000031845
Start: 2017-09-15Target: 30Updated: 2026-06-29